ArticleInternational journal of critical illness and injury science
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.
Article in International journal of critical illness and injury science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remdesivir is commonly used for inpatient treatment of coronavirus disease of 2019 (COVID-19) and may be associated with bradycardia. The objective is to investigate the incidence of bradycardia in patients with COVID-19 receiving remdesivir and evaluate potential risk factors associated with bradycardia. Methods: This single-center, retrospective, cohort study evaluated the incidence of bradycardia during and up to 48 h after remdesivir administration in adults admitted to the medical center for treatment of COVID-19. Secondary endpoints included time to bradycardia after remdesivir administration, incidence of severe bradycardia, incidence of early remdesivir discontinuation due to bradycardia, interventions to treat bradycardia, and inpatient mortality. Univariate analyses were performed to determine factors associated with remdesivir-related bradycardia. Risk factors significant at the 0.20 level in the univariate analysis were entered into a stepwise backward regression analysis to evaluate potential risk factors. Results: Bradycardia occurred in 61 (49.2%) of patients with a median nadir of 50 bpm. Median baseline heart rate (HR) was lower in patients who developed bradycardia (79 [67-89] vs. 91 [80-100] Conclusion: Remdesivir-associated bradycardia is common. Baseline HR was identified as an independent risk factor for bradycardia in hospitalized patients being treated with remdesivir for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.